Actylis, a global manufacturer and sourcing expert of critical materials and performance ingredients for the life sciences and specialty chemicals markets, has appointed Scott Thomson as Chief Executive Officer.
 
Thomson has a three-decade track record in the pharmaceutical and chemical industries, most recently as CEO of SPI Pharma, a global provider of pharmaceutical ingredients, systems and services, where he helped lead the sustainable improvement of its strategic development and execution.
 
Prior to SPI Pharma, Thomson was a senior executive at BASF and was responsible for several global life science and specialty ingredients businesses.
 
“Scott has an impressive tenure of driving long-term growth, and we look forward to welcoming Scott as we bring our client-centric, flexible customer service model and extensive product offerings to an increasing number of geographies, customers and applications,” said Rakesh Sachdev, Chairman of Actylis.
 
Thomson remarked, “I feel privileged to lead the Actylis team at this exciting juncture, and I look forward to partnering with our customers, Actylis’ management and employees, and New Mountain to grow and further develop Actylis’ offerings. There is significant opportunity to accelerate the company’s growth and I look forward to building upon the company’s achievements to date both organically and inorganically.”